NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)
Stock Stats
News
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Stifel Nicolaus from $44.00 to $50.00. They now have a "buy" rating on the stock.
Form 4 NewAmsterdam Pharma Co For: Jan 07 Filed by: van der Kamp Hilde Johanna
Form 4 NewAmsterdam Pharma Co For: Jan 07 Filed by: Lewis William
Form 4 NewAmsterdam Pharma Co For: Jan 07 Filed by: Smither John W
Form 4 NewAmsterdam Pharma Co For: Jan 07 Filed by: Davidson Michael H.
Form 4 NewAmsterdam Pharma Co For: Jan 07 Filed by: Gulfo Adele M.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.